全文获取类型
收费全文 | 191043篇 |
免费 | 15839篇 |
国内免费 | 6133篇 |
专业分类
耳鼻咽喉 | 1601篇 |
儿科学 | 2436篇 |
妇产科学 | 2154篇 |
基础医学 | 30193篇 |
口腔科学 | 3177篇 |
临床医学 | 14100篇 |
内科学 | 32451篇 |
皮肤病学 | 2671篇 |
神经病学 | 14413篇 |
特种医学 | 4142篇 |
外国民族医学 | 52篇 |
外科学 | 12944篇 |
综合类 | 25588篇 |
一般理论 | 6篇 |
预防医学 | 8694篇 |
眼科学 | 1880篇 |
药学 | 31592篇 |
60篇 | |
中国医学 | 8328篇 |
肿瘤学 | 16533篇 |
出版年
2024年 | 92篇 |
2023年 | 3525篇 |
2022年 | 4649篇 |
2021年 | 7832篇 |
2020年 | 7959篇 |
2019年 | 7976篇 |
2018年 | 5875篇 |
2017年 | 6031篇 |
2016年 | 5938篇 |
2015年 | 6967篇 |
2014年 | 11223篇 |
2013年 | 12586篇 |
2012年 | 11232篇 |
2011年 | 13070篇 |
2010年 | 10778篇 |
2009年 | 11038篇 |
2008年 | 10706篇 |
2007年 | 9758篇 |
2006年 | 8717篇 |
2005年 | 7654篇 |
2004年 | 6381篇 |
2003年 | 5708篇 |
2002年 | 4516篇 |
2001年 | 3689篇 |
2000年 | 3087篇 |
1999年 | 2686篇 |
1998年 | 2257篇 |
1997年 | 2176篇 |
1996年 | 1921篇 |
1995年 | 1942篇 |
1994年 | 1758篇 |
1993年 | 1523篇 |
1992年 | 1277篇 |
1991年 | 1205篇 |
1990年 | 989篇 |
1989年 | 830篇 |
1988年 | 790篇 |
1987年 | 665篇 |
1986年 | 600篇 |
1985年 | 945篇 |
1984年 | 900篇 |
1983年 | 629篇 |
1982年 | 639篇 |
1981年 | 511篇 |
1980年 | 431篇 |
1979年 | 353篇 |
1978年 | 230篇 |
1977年 | 193篇 |
1976年 | 183篇 |
1975年 | 123篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
1.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
2.
Anna Weiss MD Olga Martínez-Sáez MD PhD Adrienne G. Waks MD Alison Laws MD MPH Monica McGrath BA Paolo Tarantino MD Leah Portnow MD Eric Winer MD María Rey MD Marta Tapia MD Aleix Prat MD PhD Ann H. Partridge MD MPH Sara M. Tolaney MD MPH Juan M. Cejalvo MD PhD Elizabeth A. Mittendorf MD PhD MHCM Tari A. King MD 《Cancer》2023,129(12):1836-1845
3.
Yukihito Kuroda Tatsuya Oda Osamu Shimomura Shinji Hashimoto Yoshimasa Akashi Yoshihiro Miyazaki Kinji Furuya Tomoaki Furuta Hiromitsu Nakahashi Pakavarin Louphrasitthiphol Bryan J Mathis Takahito Nakajima Hiroaki Tateno 《International journal of cancer. Journal international du cancer》2023,152(7):1425-1437
Pancreatic ductal adenocarcinoma (PDAC) is resistant to current treatments but lectin-based therapy targeting cell surface glycans could be a promising new horizon. Here, we report a novel lectin-based phototherapy (Lec-PT) that combines the PDAC targeting ability of rBC2LCN lectin to a photoabsorber, IRDye700DX (rBC2-IR700), resulting in a novel and highly specific near-infrared, light-activated, anti-PDAC therapy. Lec-PT cytotoxicity was first verified in vitro with a human PDAC cell line, Capan-1, indicating that rBC2-IR700 is only cytotoxic upon cellular binding and exposure to near-infrared light. The therapeutic efficacy of Lec-PT was subsequently verified in vivo using cell lines and patient-derived, subcutaneous xenografting into nude mice. Significant accumulation of rBC2-IR700 occurs as early as 2 hours postintravenous administration while cytotoxicity is only achieved upon exposure to near-infrared light. Repeated treatments further slowed tumor growth. Lec-PT was also assessed for off-target toxicity in the orthotopic xenograft model. Shielding of intraperitoneal organs from near-infrared light minimized off-target toxicity. Using readily available components, Lec-PT specifically targeted pancreatic cancer with high reproducibility and on-target, inducible toxicity. Rapid clinical development of this method is promising as a new modality for treatment of pancreatic cancer. 相似文献
4.
Tie Zhou Shengfei Qin Weidong Xu Shouyan Tang Guanghua Chen Song Li Jianguo Hou Xu Gao Guowei Shi Zhongquan Sun Jie Jin Lijun Chen Weibing Sun Ben Liu Jingen Wang Qinggui Meng Dongwen Wang Zhiquan Hu Dalin He Yong Yang Xishuang Song Cheng Fu Yinhuai Wang Dingwei Ye Wei Zhang 《International journal of cancer. Journal international du cancer》2023,153(4):792-802
We aim to assess the safety and efficacy of proxalutamide, a novel androgen receptor antagonist, for men with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter, randomized, open-label, phase 2 trial. In our study, the enrolled mCRPC patients were randomized to 100, 200 and 300 mg dose groups at 1:1:1. The primary efficacy endpoint was prostate-specific antigen (PSA) response rate. The secondary endpoints included objective response rate (ORR), disease control rate (DCR) and time to PSA and radiographic progression. Safety and pharmacokinetics were also assessed. Finally, there were 108 patients from 17 centers being enrolled. By week 16, there were 13 (35.1%), 12 (36.4%) and 15 (42.9%) patients with confirmed 50% or greater PSA decline in 100 mg (n = 37), 200 mg (n = 33) and 300 mg (n = 35) groups, respectively. Among the 19 patients with target lesions at study entry, three (15.8%) had a partial response and 12 (63.2%) had stable disease. The ORRs of 20.0%, 22.2%, 0% and DCRs of 80.0%, 88.9%, 60.0% were, respectively, achieved in 100, 200 and 300 mg groups. By the maximum follow-up time of 24 weeks, there were 42.6% and 10.2% of cases experiencing PSA progression and radiographic progression, respectively. Overall, adverse events (AEs) were experienced by 94.4% of patients, most of which were mild or moderate. There were 28 patients experiencing ≥grade 3 AEs. The most common AEs were fatigue (17.6%), anemia (14.8%), elevated AST (14.8%) and ALT (13.0%), decreased appetite (13.0%). These findings preliminarily showed the promising antitumor activity of proxalutamide in patients with mCRPC with a manageable safety profile. The proxalutamide dose of 200 mg daily is recommended for future phase 3 trial (Clinical trial registration no. CTR20170177). 相似文献
5.
Shuang Lu Hong Sun Kim Yubo Cao Karan Bedi Lili Zhao Ishwarya Venkata Narayanan Brian Magnuson Yumei Gu Jing Yang Zhujun Yi Sepideh Babaniamansour Sargis Shameon Chang Xu Michelle T. Paulsen Ping Qiu Sivakumar Jeyarajan Mats Ljungman Dafydd Thomas Yali Dou Howard Crawford Marina Pasca di Magliano Kai Ge Bo Yang Jiaqi Shi 《International journal of cancer. Journal international du cancer》2023,153(3):552-570
6.
Mingxia Jiang Jiaxuan Liu Qiao Li Binghe Xu 《International journal of cancer. Journal international du cancer》2023,153(7):1324-1336
Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase receptor that plays a carcinogenic role in breast cancer (BC) through gene amplification, mutation, or overexpression. Traditional methods of HER2 detection were divided into positive (immunohistochemistry (IHC) 3+/fluorescence in situ hybridization (FISH) amplification) and negative (IHC 2+/FISH−, IHC 1+, IHC 0) according to the dichotomy method. Anti-HER2-targeted therapies, such as trastuzumab and pertuzumab, have significantly improved the prognosis of HER2-positive patients. However, up to 75% to 85% of patients remain HER2-negative. In recent years, with the rapid development of molecular biology, gene detection technology, targeted therapy, and immunotherapy, researchers have actively explored the clinicopathological characteristics, molecular biological characteristics, treatment methods, and HER2 detection methods of HER2-low/zero breast cancer. With the clinical efficacy of new anti-HER2 targeted drugs, accurate classification of breast cancer is very important for the treatment choice. Therefore, the following review summarizes the necessity of developing HER2 detection methods, and the clinicopathological and drug treatment characteristics of patients with HER2-low/zero, to light the dawn of the treatment of breast cancer patients with HER2-low/zero expression. 相似文献
7.
Bartlomiej Gielniewski Katarzyna Poleszak Adria-Jaume Roura Paulina Szadkowska Karol Jacek Sylwia K. Krol Rafal Guzik Paulina Wiechecka Marta Maleszewska Beata Kaza Andrzej Marchel Tomasz Czernicki Andrzej Koziarski Grzegorz Zielinski Andrzej Styk Maciej Kawecki Cezary Szczylik Ryszard Czepko Mariusz Banach Wojciech Kaspera Wojciech Szopa Mateusz Bujko Bartosz Czapski Miroslaw Zabek Ewa Iżycka-Świeszewska Wojciech Kloc Pawel Nauman Joanna Cieslewicz Wieslawa Grajkowska Natalia Morosini Houtan Noushmehr Bartosz Wojtas Bozena Kaminska 《International journal of cancer. Journal international du cancer》2023,153(5):1003-1015
8.
9.
The Effects of Protein Phosphatase 2A Activation with Novel Tricyclic Sulfonamides on Hepatoblastoma
《Journal of pediatric surgery》2023,58(6):1145-1154
BackgroundThe tumor suppressor, protein phosphatase 2A (PP2A), is downregulated in hepatoblastoma. We aimed to examine the effects of two novel compounds of the tricyclic sulfonamide class, ATUX-3364 (3364) and ATUX-8385 (8385), designed to activate PP2A without causing immunosuppression, on human hepatoblastoma.MethodsAn established human hepatoblastoma cell line, HuH6, and a human hepatoblastoma patient-derived xenograft, COA67, were treated with increasing doses of 3364 or 8385, and viability, proliferation, cell cycle and motility were investigated. Cancer cell stemness was evaluated by real-time PCR and tumorsphere forming ability. Effects on tumor growth were examined using a murine model.ResultsTreatment with 3364 or 8385 significantly decreased viability, proliferation, cell cycle progression and motility in HuH6 and COA67 cells. Both compounds significantly decreased stemness as demonstrated by decreased abundance of OCT4, NANOG, and SOX2 mRNA. The ability of COA67 to form tumorspheres, another sign of cancer cell stemness, was significantly diminished by 3364 and 8385. Treatment with 3364 resulted in decreased tumor growth in vivo.ConclusionNovel PP2A activators, 3364 and 8385, decreased hepatoblastoma proliferation, viability, and cancer cell stemness in vitro. Animals treated with 3364 had decreased tumor growth. These data provide evidence for further investigation of PP2A activating compounds as hepatoblastoma therapeutics. 相似文献
10.
Andreas Lundin Martin Annborn Ola Borgquist Joachim Düring Johan Undén Christian Rylander 《Acta anaesthesiologica Scandinavica》2023,67(5):655-662
Patients admitted to intensive care after cardiac arrest are at risk of circulatory shock and early mortality due to cardiovascular failure. The aim of this study was to evaluate the ability of the veno-arterial pCO2 difference (∆pCO2; central venous CO2 – arterial CO2) and lactate to predict early mortality in postcardiac arrest patients. This was a pre-planned prospective observational sub-study of the target temperature management 2 trial. The sub-study patients were included at five Swedish sites. Repeated measurements of ∆pCO2 and lactate were conducted at 4, 8, 12, 16, 24, 48, and 72 h after randomization. We assessed the association between each marker and 96-h mortality and their prognostic value for 96-h mortality. One hundred sixty-three patients were included in the analysis. Mortality at 96 h was 17%. During the initial 24 h, there was no difference in ∆pCO2 levels between 96-h survivors and non-survivors. ∆pCO2 measured at 4 h was associated with an increased risk of death within 96 h (adjusted odds ratio: 1.15; 95% confidence interval [CI]: 1.02–1.29; p = .018). Lactate levels were associated with poor outcome over multiple measurements. The area under the receiving operating curve to predict death within 96 h was 0.59 (95% CI: 0.48–0.74) and 0.82 (95% CI: 0.72–0.92) for ∆pCO2 and lactate, respectively. Our results do not support the use of ∆pCO2 to identify patients with early mortality in the postresuscitation phase. In contrast, non-survivors demonstrated higher lactate levels in the initial phase and lactate identified patients with early mortality with moderate accuracy. 相似文献